Can-Fite's Namodenoson Shows Early Promise in Pancreatic Cancer Trial
Event summary
- Can-Fite's Phase 2a pancreatic cancer study with namodenoson completed enrollment, showing prolonged disease control in several patients, including one with 16-month durability.
- Namodenoson demonstrated RAS signaling inhibition, aligning with growing clinical validation of RAS inhibition in pancreatic cancer highlighted at ASCO 2026.
- The drug has Orphan Drug Designation from the FDA for pancreatic cancer treatment.
- Namodenoson targets RAS, Wnt/β-catenin, and NF-κB signaling pathways, offering a differentiated approach with a favorable safety profile.
The big picture
The growing momentum for RAS inhibition in oncology, underscored by ASCO 2026, positions Can-Fite's namodenoson as a potential differentiator in pancreatic cancer treatment. With KRAS mutations driving approximately 90% of pancreatic cancers, therapies like namodenoson that modulate this signaling network are critically needed. Can-Fite's ability to leverage its multi-pathway mechanism and favorable safety profile could enhance its competitive stance in this high-unmet-need indication.
What we're watching
- Clinical Validation
- How the durability of responses in the Phase 2a study will influence the design and timing of potential Phase 3 trials for namodenoson in pancreatic cancer.
- Regulatory Pathway
- Whether the Orphan Drug Designation and favorable safety profile will accelerate FDA review and approval processes for namodenoson.
- Competitive Positioning
- The pace at which Can-Fite can differentiate namodenoson from other RAS-targeting therapies in development, particularly in the aggressive pancreatic cancer market.
Related topics